Our Experts

headshot-john-griggs-meet-the-expert

John Griggs

Senior Manager Solutions Consulting

Expertise: Policy and Regulation, Oncology and Rare Disease, Real-World Data, Marketing and Promotion, Contracting, Reimbursement and Rebates, Product Launch, Commercial Strategy, Payer Coverage and Restrictions

John Griggs is a senior manager in Solutions Consulting at MMIT. He supports aligning MMIT solutions to pharma business needs and questions during the entire lifecycle of specialty medications, from pre-launch to LOE. John has worked for the company for more than a decade, and has extensive experience in market access trends within oncology and immunology. He holds a bachelor’s in Chemical Engineering and a master’s in Materials Engineering from the Stevens Institute of Technology.

Insights by John Griggs

Article | March 8, 2022

Will New Approaches to Medical Benefit Contracting Help Control Specialty Drug Spend?

Pharmacy benefit contracting has always been a mechanism for payers to offset the cost of small-molecule therapeutic areas. Payers have looked to manufacturers to negotiate contracts that would prevent their products from being placed on a restrictive tier, or subject them to step edits or an NDC block.

Article | January 27, 2022

As We Head Into 2022, Here’s What’s Ahead for Market Access

While COVID-19 has left no industry untouched, it’s safe to say that healthcare has been hit the hardest. Yet despite this reality, there are plenty of exciting advancements happening within the industry, even amid the lingering effects of the global pandemic.

Article | October 6, 2021

Why Pharma Companies Need a Strategy to Track Market Access in Real-Time

Today, increasing market complexity and outsize payer influence have resulted in numerous hurdles to ensuring adequate access, from prior authorizations to step therapy to label restrictions.

Article | September 23, 2021

The Power of Partnerships: Why Pharma Needs to Redefine its Role With IDNs

Large healthcare conglomerates, or integrated delivery networks (IDNs), have long been fixtures in the market access landscape—a dynamic that has gone unchanged despite the disruption caused by COVID-19.
Stay In Touch

Be the first to know about new arrivals and promotions

Reducing Risk: 5 Steps for a Fearless Launch